Nunatak Capital

Nunatak Capital is a small venture firm with website, LinkedIn and Crunchbase presence but no disclosed healthcare sub-vertical thesis, AI focus, stage preference or check size in the source data. The name evokes a long-duration, patient-capital posture, which often correlates with generalist early-stage investing rather than deep sector specialization. Founders should treat Nunatak as a possible seed or pre-seed participant rather than a domain-specialist lead, with plausible check sizes in the $100K to $1M range and limited reserve capacity for follow-ons. The firm is most plausibly relevant for healthcare-adjacent software, digital health, wellness and B2B SaaS targeting healthcare buyers where general-purpose venture pattern-matching applies. Founders building therapeutics, regulated devices, diagnostics, or businesses requiring payer-contracting expertise should look elsewhere; Nunatak is unlikely to provide the regulatory, clinical or commercial diligence depth those founders need. Founders pitching deep clinical AI should expect to educate the firm on FDA pathways, hospital sales cycles and reimbursement dynamics rather than draw on an existing knowledge base. Entry is best attempted via LinkedIn outreach to named partners, ideally warmed up by a portfolio founder or mutual investor. In any first conversation, push for clarity on fund size, deployment pace, healthcare exposure in the existing portfolio, and whether the firm has lead capacity or only participates. Until more public signal appears, Nunatak belongs on a long list of potential check-fillers rather than a target lead investor for a healthcare round.